Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Scala

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Cells|November 11, 2022
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected PatientsCrescenzo D'Alterio, Alessandro Giardino, Giosuè Scognamiglio, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Prospective clinical trials of biotherapies in solid tumors: a 5-year surveyAlessandro Ottaiano, Ernesto Mollo, Giuseppe Di Lorenzo, et al.
Cellular & Molecular Immunology|November 4, 2014
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does notMaria Neve Polimeno, Caterina Ierano, Crescenzo D'Alterio, et al.
Oncotarget|November 5, 2017
Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancerSara Santagata, Maria Napolitano, Crescenzo D'Alterio, et al.
British Journal of Pharmacology|November 26, 2021
Sphingosine-1-phosphate/TGF-β axis drives epithelial mesenchymal transition in asthma-like diseaseMaria A Riemma, Ida Cerqua, Barbara Romano, et al.
Journal of Medicinal Chemistry|November 11, 2017
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) AntagonistSalvatore Di Maro, Francesco Saverio Di Leva, Anna Maria Trotta, et al.
International Journal of Cancer|December 31, 2013
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patientsCrescenzo D'Alterio, Antonio Avallone, Fabiana Tatangelo, et al.
Plos One|December 19, 2024
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cellsDaniela Russo, Anna Spina, Luigi Portella, et al.
Cell Cycle (Georgetown, Tex.)|March 24, 2009
A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migrationCaterina Ierano, Paola Giuliano, Crescenzo D'Alterio, et al.
International Journal of Molecular Sciences|August 12, 2022
Tailoring the Structure of Cell Penetrating DNA and RNA Binding NucleopeptidesStefano Tomassi, Caterina Ieranò, Alessandra Del Bene, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Cells|November 11, 2022
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected PatientsCrescenzo D'Alterio, Alessandro Giardino, Giosuè Scognamiglio, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Prospective clinical trials of biotherapies in solid tumors: a 5-year surveyAlessandro Ottaiano, Ernesto Mollo, Giuseppe Di Lorenzo, et al.
Cellular & Molecular Immunology|November 4, 2014
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does notMaria Neve Polimeno, Caterina Ierano, Crescenzo D'Alterio, et al.
Oncotarget|November 5, 2017
Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancerSara Santagata, Maria Napolitano, Crescenzo D'Alterio, et al.
British Journal of Pharmacology|November 26, 2021
Sphingosine-1-phosphate/TGF-β axis drives epithelial mesenchymal transition in asthma-like diseaseMaria A Riemma, Ida Cerqua, Barbara Romano, et al.
Journal of Medicinal Chemistry|November 11, 2017
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) AntagonistSalvatore Di Maro, Francesco Saverio Di Leva, Anna Maria Trotta, et al.
International Journal of Cancer|December 31, 2013
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patientsCrescenzo D'Alterio, Antonio Avallone, Fabiana Tatangelo, et al.
Plos One|December 19, 2024
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cellsDaniela Russo, Anna Spina, Luigi Portella, et al.
Cell Cycle (Georgetown, Tex.)|March 24, 2009
A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migrationCaterina Ierano, Paola Giuliano, Crescenzo D'Alterio, et al.
International Journal of Molecular Sciences|August 12, 2022
Tailoring the Structure of Cell Penetrating DNA and RNA Binding NucleopeptidesStefano Tomassi, Caterina Ieranò, Alessandra Del Bene, et al.
Pageof 13